Endologix Inc. (NASDAQ:ELGX)’s share price rose 3.4% during mid-day trading on Monday . The company traded as high as $12.07 and last traded at $12.02, with a volume of 309,245 shares traded. The stock had previously closed at $11.63.

A number of research firms have commented on ELGX. Royal Bank Of Canada upped their price target on Endologix from $11.00 to $15.00 and gave the company an “outperform” rating in a research report on Tuesday, May 10th. BMO Capital Markets reiterated a “hold” rating and issued a $11.50 price target on shares of Endologix in a research report on Tuesday, May 10th. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of Endologix in a research report on Tuesday, May 10th. Canaccord Genuity reiterated a “hold” rating on shares of Endologix in a research report on Tuesday, May 10th. Finally, BTIG Research reiterated a “buy” rating on shares of Endologix in a research report on Sunday, May 29th. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $13.86.

The stock has a 50-day moving average of $12.84 and a 200 day moving average of $11.15. The stock’s market cap is $992.58 million.

Endologix (NASDAQ:ELGX) last released its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.07. During the same quarter in the previous year, the business earned ($0.18) EPS. The firm had revenue of $51 million for the quarter, compared to analysts’ expectations of $46.30 million. The company’s revenue for the quarter was up 29.1% on a year-over-year basis. Equities research analysts expect that Endologix Inc. will post ($0.74) EPS for the current year.

In other news, VP Jose A. Lima sold 4,710 shares of Endologix stock in a transaction dated Friday, August 19th. The stock was sold at an average price of $11.68, for a total value of $55,012.80. Following the transaction, the vice president now owns 42,594 shares in the company, valued at $497,497.92. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, President Robert D. Mitchell sold 2,294 shares of Endologix stock in a transaction dated Wednesday, June 1st. The stock was sold at an average price of $12.55, for a total value of $28,789.70. Following the completion of the transaction, the president now owns 318,233 shares in the company, valued at approximately $3,993,824.15. The disclosure for this sale can be found here.

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.